- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pharma Leads the Way in M&A
The pharma, medical and biotech industry is the leading sector for M&A activity this year, Mergermarket‘s Q2 M&A stats reveal.
The pharma, medical and biotech industry is the leading sector for M&A activity this year, Mergermarket‘s Q2 M&A stats reveal. The sector’s deals have been valued at US$252.5 bn, a 16.9% market share in global M&A. Deal value is 48.2% above the whole of 2013’s value, and four deals account for a 61.3% share in the sector’s total activity.
Pharma, medical and biotech companies were the most targeted during the first six months of 2014, says Mergermarket; the value already exceeds the annual values of every other year since 2006.
Deals valued at US$ 84.8 bn currently have a 19.9% share in total European M&A, a considerable increase from a 5.4% share this time last year. US bidders accounted for a 71.8% share of European pharma, medical and biotech M&A activity, with deals being announced for tax benefits such as the US$ 45.9bn acquisition of Ireland’s Covidien by Medtronic.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
